The Cigna Group Q4 2025 Earnings & 2026 Outlook

2025 Financial Highlights & 2026 Outlook

• 💡 The Cigna Group reported full-year 2025 adjusted revenue of $275 billion, an 11% increase, and adjusted earnings per share (EPS) of $29.84, up 9%.
• 📈 For 2026, the company projects consolidated adjusted revenues of approximately $280 billion and adjusted EPS of at least $30.25, reinforcing sustained growth.
• 💰 Over $5 billion was returned to shareholders in 2025 through dividends and share repurchases.

FTC Settlement & Pharmacy Benefits Model

• ✅ A global settlement with the Federal Trade Commission (FTC) resolved all matters regarding the pharmacy benefits business, including an industry-wide insulin lawsuit.
• 🎯 The settlement is expected to provide $7 billion in out-of-pocket cost relief over 10 years for 100 million customers, increasing transparency and strengthening community pharmacist relationships.
• 💡 Cigna's new rebate-free pharmacy benefits model, developed in early 2025, aligns with the settlement's goals by focusing on lowest out-of-pocket costs for consumers and a transparent, fee-based structure.
• 🔄 The company anticipates the margin profile and growth algorithm for its pharmacy benefit services will remain similar despite the model transition.

Driving Healthcare Affordability

• 🧠 Cigna is actively confronting underlying healthcare cost drivers, including rapidly growing demand (aging population, chronic conditions) and rising supply costs (hospital stays, new drug launches).
• 🛠️ Strategies include investing in portfolio shaping to collaborate rather than own care delivery, informing decisions on care location, and fostering meaningful partnerships (e.g., Evernorth with Trump RX for fertility treatments).
• 📉 Efforts to minimize administrative burden led to a 15% reduction in prior authorizations over the past year.
• 💊 The company leverages competition with generics and biosimilars, offering zero out-of-pocket options for widely used brand-name medications like Humira and Stelara, projecting over $100 billion in biosimilar savings for the US.

Segment Performance & Innovations

• 🚀 Evernorth's Specialty and Care Services achieved 14% adjusted revenue growth and 13% year-over-year growth in specialty scripts in 2025, driven by demand and biosimilar shifts.
• 💡 Cigna Healthcare delivered strong results with disciplined pricing and introduced AI-powered digital tools for provider matching and real-time cost tracking, alongside partnerships for fertility and mental health support.
• ✨ New offerings like "Clarity" in Cigna Healthcare provide customers with cost transparency and a simple co-pay structure, aiming for up to 10% medical cost savings for clients.

Capital Management & Future Outlook

• 📊 Cigna reported $9.6 billion in cash flow from operations for 2025 and expects approximately $9 billion in 2026, with the majority realized in the second half.
• 🎯 The company is progressing towards a long-term debt to capitalization ratio of approximately 40%, having improved to 43% in 2025.
• 📈 The Medical Care Ratio (MCR) outlook for 2026 is 83.7% to 84.7%, reflecting pricing actions and an elevated cost environment, while total medical customers are expected to remain flat at 18.1 million.